{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:38:02Z","timestamp":1786711082937,"version":"build-2736575974"},"reference-count":31,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Medicine and Pharmacy Carol Davila"},{"id":[{"id":"https:\/\/ror.org\/04fm87419","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Actinic keratoses (AKs) are skin conditions that arise from the proliferation of atypical keratinocytes and are considered precursors to cutaneous squamous cell carcinoma. There are several treatment options available, which can be categorized into two main groups: lesion-directed therapies and field-directed therapies. Tirbanibulin 1% ointment has emerged as a new treatment for AKs. We conducted a meta-analysis to evaluate the effectiveness of tirbanibulin by analyzing the rates of complete clearance (CC) and partial clearance (PC) in randomized controlled trials (RCTs) and real-world studies. Our search included four databases: PubMed, Google Scholar, Scopus, and Web of Science. After applying specific inclusion and exclusion criteria, we identified 11 study cohorts from 10 publications. The CC rate was reported in 10 of the 11 studies, involving a total of 2092 patients, with 874 CC events observed. This resulted in an overall pooled CC rate of 52.05% (95% CI: 42.43\u201361.52%). The PC rate was also reported in 10 of the 11 studies, involving a total of 2367 patients, with 1631 PC events recorded. This led to an overall pooled PC rate of 71.96% (95% CI: 64.89\u201378.09%). In conclusion, tirbanibulin 1% ointment has shown clinical effectiveness and should be considered a promising treatment for AKs.<\/jats:p>","DOI":"10.3390\/life16081330","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T17:01:35Z","timestamp":1786640495000},"page":"1330","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Clearance of Actinic Keratoses with Tirbanibulin 1% Ointment: Evidence from a Meta-Analysis"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4983-7648","authenticated-orcid":false,"given":"Mircea","family":"Tampa","sequence":"first","affiliation":[{"name":"Department of Dermatology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Dermatology, \u2018Victor Babes\u2019 Clinical Hospital for Infectious Diseases, 030303 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Matei","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina Irina","family":"Mitran","sequence":"additional","affiliation":[{"name":"Department of Microbiology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Iulia","family":"Mitran","sequence":"additional","affiliation":[{"name":"Department of Microbiology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1949-7323","authenticated-orcid":false,"given":"Weeratian","family":"Tawanwongsri","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Internal Medicine, School of Medicine, Walailak University, Nakhon Si Thammarat 80160, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Loredana","family":"Chiriac","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0574-0839","authenticated-orcid":false,"given":"Ecaterina","family":"Rinja","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Clinical Emergency Hospital of Bucharest, 014461 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina Daniela","family":"Ene","sequence":"additional","affiliation":[{"name":"Department of Nephrology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Nephrology, \u2018Carol Davila\u2019 Nephrology Hospital, 010731 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilinca","family":"Nicolae","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u2018Victor Babes\u2019 Clinical Hospital for Infectious Diseases, 030303 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0544-4068","authenticated-orcid":false,"given":"Milena","family":"Tocut","sequence":"additional","affiliation":[{"name":"Israel Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel"},{"name":"Internal Medicine C Department, Wolfson Medical Center, Holon 58100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona Roxana","family":"Georgescu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Department of Dermatology, \u2018Victor Babes\u2019 Clinical Hospital for Infectious Diseases, 030303 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Li, Z., Lu, F., Zhou, F., Song, D., Chang, L., Liu, W., Yan, G., and Zhang, G. (2025). From Actinic Keratosis to Cutaneous Squamous Cell Carcinoma: The Key Pathogenesis and Treatments. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1518633"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e2024147S","DOI":"10.5826\/dpc.1403S1a147S","article-title":"Clinical and Dermoscopic Diagnosis of Actinic Keratosis","volume":"14","author":"Conforti","year":"2024","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5114\/ada.2024.147331","article-title":"Actinic Keratosis: Comprehensive Review of Current Treatments and Emerging Therapeutic Innovations","volume":"42","author":"Ceryn","year":"2025","journal-title":"Adv. Dermatol. Allergol. Dermatol. Alergol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.2147\/CCID.S374122","article-title":"Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action","volume":"15","author":"Schlesinger","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e2024145S","DOI":"10.5826\/dpc.1403S1a145S","article-title":"Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment","volume":"14","author":"Valenti","year":"2024","journal-title":"Dermatol. Pract. Concept."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/10600280211031329","article-title":"1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses","volume":"56","author":"Dao","year":"2022","journal-title":"Ann. Pharmacother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br. Med. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1056\/NEJMoa2024040","article-title":"Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis","volume":"384","author":"Blauvelt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Campione, E., Rivieccio, A., Gaeta Shumak, R., Costanza, G., Cosio, T., Lambiase, S., Garofalo, V., Artosi, F., Lozzi, F., and Freni, C. (2023). Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses. Pharmaceuticals, 16.","DOI":"10.3390\/ph16121686"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1018395","DOI":"10.1155\/2024\/1018395","article-title":"Tirbanibulin 1% Ointment Effectiveness for Actinic Keratosis Treatment Evaluated by Dynamic Optical Coherence Tomography","volume":"2024","author":"Cantisani","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1111\/jdv.70217","article-title":"Tirbanibulin 1% Real-world Use in 679 Actinic Keratoses Patients during Warm Season (SUMM-AK Study)","volume":"40","author":"Carugno","year":"2026","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"104632","DOI":"10.1016\/j.ad.2026.104632","article-title":"Patient- and Clinician-Reported Outcomes, Safety and Efficacy Profile of Tirbanibulin 1% for Actinic Keratosis Under Conditions Close to Routine Clinical Practice in Spain and Italy (TIRBASKIN Study)","volume":"117","author":"Gilaberte","year":"2026","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"ref_13","first-page":"186","article-title":"Real-world Evidence of Tirbanibulin in the Treatment of Actinic Keratosis in Germany\u2014Prospective, Multicenter, Non-interventional KLIR Study","volume":"24","author":"Heppt","year":"2026","journal-title":"JDDG J. Dtsch. Dermatol. Ges."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.36849\/JDD.2020.5576","article-title":"Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results","volume":"19","author":"Kempers","year":"2020","journal-title":"J. Drugs Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"338","DOI":"10.36849\/JDD.8264","article-title":"Patient- and Clinician-Reported Outcomes for Tirbanibulin in Actinic Keratosis in Clinical Practice Across the United States (PROAK)","volume":"23","author":"Schlesinger","year":"2024","journal-title":"J. Drugs Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"105359","DOI":"10.1016\/j.pdpdt.2026.105359","article-title":"Randomized Comparative Study of 5-Fluorouracil 4%, Tirbanibulin, and Photodynamic Therapy for Relapsing Actinic Keratoses","volume":"58","author":"Venturi","year":"2026","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"adv42927","DOI":"10.2340\/actadv.v105.42927","article-title":"Field Cancerization Treatment with Tirbanibulin 1% Ointment: Results in Real-World Practice","volume":"105","year":"2025","journal-title":"Acta Derm. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40261-021-01068-9","article-title":"Tirbanibulin: Topical Treatment for Actinic Keratosis","volume":"41","author":"Dlott","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e14833","DOI":"10.1111\/dth.14833","article-title":"Patient-reported Outcomes of Topical Therapies in Actinic Keratosis: A Systematic Review","volume":"34","author":"Grada","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"19913s13","DOI":"10.36849\/JDD.19913","article-title":"Tirbanibulin 1% Ointment: The Mechanism of Action of a Novel Topical Therapy for Actinic Keratosis","volume":"24","author":"Roberts","year":"2025","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_21","first-page":"27","article-title":"A Review on Functions of Src Family Kinase in Epidermal Maintenance, Wound Recuperation, and Cancer Formation","volume":"1","author":"Khatun","year":"2025","journal-title":"J. Biosci. Public Health"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/exd.13902","article-title":"Topical Kinase Inhibitors Induce Regression of Cutaneous Squamous Cell Carcinoma","volume":"28","author":"Yang","year":"2019","journal-title":"Exp. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jdin.2024.07.001","article-title":"Safety and Tolerability of Tirbanibulin Ointment 1% Treatment on 100 Cm2 of the Face or Scalp in Patients with Actinic Keratosis: A Phase 3 Study","volume":"17","author":"Bhatia","year":"2024","journal-title":"JAAD Int."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Li Pomi, F., Vaccaro, M., Pallio, G., Rottura, M., Irrera, N., and Borgia, F. (2024). Tirbanibulin 1% Ointment for Actinic Keratosis: Results from a Real-Life Study. Medicina, 60.","DOI":"10.3390\/medicina60020225"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/1346-8138.17845","article-title":"Tirbanibulin 1% Ointment for the Treatment of Hyperkeratotic Actinic Keratosis","volume":"52","author":"Rottura","year":"2025","journal-title":"J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kirchberger, M.C., Gfesser, M., Erdmann, M., Schliep, S., Berking, C., and Heppt, M.V. (2023). Tirbanibulin 1% Ointment Significantly Reduces the Actinic Keratosis Area and Severity Index in Patients with Actinic Keratosis: Results from a Real-World Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12144837"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Steeb, T., Wessely, A., Harla\u00df, M., Heppt, F., Koch, E.A.T., Leiter, U., Garbe, C., Sch\u00f6ffski, O., Berking, C., and Heppt, M.V. (2020). A Systematic Review and Meta-Analysis of Interventions for Actinic Keratosis from Post-Marketing Surveillance Trials. J. Clin. Med., 9.","DOI":"10.3390\/jcm9072253"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1111\/jocd.16475","article-title":"Comparison of Therapeutic Agents\u2019 Short-term Effects on Facial and Scalp Actinic Keratosis: A Network Meta-analysis","volume":"23","author":"Gupta","year":"2024","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Heppt, M.V., Dykukha, I., Graziadio, S., Salido-Vallejo, R., Chapman-Rounds, M., and Edwards, M. (2022). Comparative Efficacy and Safety of Tirbanibulin for Actinic Keratosis of the Face and Scalp in Europe: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. J. Clin. Med., 11.","DOI":"10.3390\/jcm11061654"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jdrv.2026.02.012","article-title":"Efficacy and Safety of Tirbanibulin 1% Ointment for Actinic Keratosis: A Systematic Review and Meta-Analysis","volume":"8","author":"Callegaro","year":"2026","journal-title":"JAAD Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jdin.2024.11.005","article-title":"Real-World Experience with Tirbanibulin 1% Ointment for the Treatment of Nonmelanoma Skin Cancer Following Cryotherapy: A Pilot Study","volume":"18","author":"Moore","year":"2024","journal-title":"JAAD Int."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/8\/1330\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T12:03:48Z","timestamp":1786709028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/8\/1330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["life16081330"],"URL":"https:\/\/doi.org\/10.3390\/life16081330","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}